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Before the 1980s, a number of diseases of
animals (scrapie, chronic wasting disease, and
transmissible mink encephalopathy) and hu-
mans (Creutzfeldt-Jakob disease, Gerstmann-
Straussler-Scheinker syndrome, and kuru), in
spite of distinctive individual features, could be
unified by the term transmissible spongiform
encephalopathies (TSEs). In 1986, bovine
spongiform encephalopathy (BSE) was first
identified in indigenous cattle in the United
Kingdom (1). A variety of clinical signs have been
observed, but the three cardinal features of the
disease are nervousness, heightened reactivity to
external stimuli, and difficult movement, particu-
larly of the hind limbs (2).  Spongiform change is
evident in the brain (1), and neuropathologic tests
remain the mainstay of a BSE diagnosis. The
disease was transmitted experimentally to mice (3)
and cattle (4) by use of brain homogenates from
cattle with clinical BSE; thus BSE has all the
features that define classical TSEs.
The BSE Epidemic
Some 1985 cases were diagnosed retrospec-
tively; other cases occurring before 1986 probably
went unnoticed. Since BSE was recognized, more
than 170,000 cases were reported in the United
Kingdom through the end of 1997. The epidemic
curve, which peaked in 1992, is now in rapid
decline (Table 1). Approximately two thirds of
the dairy herds in the United Kingdom have
had at least one case of BSE compared with
only one sixth of the beef suckler herds.
Furthermore, most of the affected suckler
herds contained animals originating from dairy
herds, which are fed differently.
Shortly after the recognition of BSE,
epidemiologic studies indicated that the source of
infection was the meat and bone meal used in
concentrated cattle feed (5). Subsequently, in
July 1988, ruminant protein in ruminant feed
was banned. This ban immediately reduced the
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Table 1.  Annual incidence of bovine spongiform
encephalopathy in the United Kingdom, 1985–1997
Year Number of cases
1985        14
1986        60
1987      630
1988   2,184
1989   7,137
1990 14,181
1991 25,032
1992 36,682
1993 34,370
1994 23,945
1995 14,300
1996   8,016
1997   4,052391 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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incidence of new infections, which began to be
reflected in a diminution in the incidence of
clinical cases 5 years later (the average
incubation period) in 1993. Nevertheless, almost
36,000 cattle with BSE were born after the
ruminant feed ban (a few as late as 1994), which
indicates that the ban was not completely
effective. Ruminant protein could be included in
pig and poultry feed, and cross-contamination of
cattle feed in the production mills and perhaps
accidental exposure of cattle on the farm were
possible until the feeding of mammalian protein
to all farm animal species in the United Kingdom
was prohibited in 1996.
The average age at which clinical BSE
manifests itself is 4 to 5 years (6). Many animals
in the national U.K. herd are slaughtered at
significantly younger ages, and those infected
with BSE would not have had a chance to develop
the disease. Using methods developed for the
retrospective analysis of the AIDS epidemic,
Anderson and colleagues (7) calculated that
approximately one million animals in the U.K.
herd must have been infected to have produced
170,000 clinical cases of BSE. These same
workers predicted the number of cases of BSE
that would occur in 1996 and in subsequent years
(Table 2). The calculations are based on a
dominant feedborne source of infection; a small
amount of cow-to-calf transmission was included
because a long-term study, conducted by the U.K.
Ministry of Agriculture, Fisheries and Food,
indicated an increased incidence of BSE in calves
born to mothers in the late stages of the
incubation period of the disease (8). The results
are compatible with a cow-to-calf transmission of
approximately 10%, which in itself is not
sufficient to perpetuate the BSE epidemic. The
calculations predict a small number of cases and
very few new infections by the beginning of the
next decade. The predictions have been validated
by the actual numbers in 1996 and 1997, which
were 8,016 and 4,149, respectively (9).
Infection in Other Animals
BSE has also been transmitted to exotic
ruminants in zoos in the United Kingdom.
Between 1986 and 1992, cases have occurred in
bison, nyala, gemsbok, two species of oryx,
greater kudu, and eland. These animals became
infected by eating the same meat and bone meal-
containing concentrated feed responsible for the
disease in cattle. BSE infection in species other
than ruminants was always considered possible.
Careful watch was kept on the packs of hounds
used for hunting in the United Kingdom because
they are often fed carcasses unfit for human
consumption. Spongiform encephalopathy has
not occurred in dogs; however, in 1990, a case of
spongiform encephalopathy was diagnosed in
domestic cats; 81 additional cases in cats have
occurred with a wide geographic spread
throughout the United Kingdom. The true
incidence is probably many times higher than
observed because diagnosis is patchy and the
disease was not statutorily notifiable until 1994.
The annual incidence at the height of the
outbreak was probably 10 to 15 cases per million
cats (Wilesmith, pers. comm.). The most likely
source of the infection was commercially
produced cat food. In 1989, the pet food industry
removed the dangerous bovine tissues, the
specified bovine offal, before a statutory ban in
1990. The number of cases of feline spongiform
encephalopathy (FSE) diagnosed in the United
Kingdom has been declining since 1994 (1994, 16
cases; 1995, 6 cases; 1997, 6 cases) (Table 3). Only
one cat, an adopted stray, was apparently born
Table 2. Predictions of new infections and cases of
BSEa from 1996-2001b
New infections Cases
95% 95%
Expected Prediction Expected Prediction
Year value interval value interval
1996 189 (155-11,300) 7,386 (6,541-8,856)
1997   95        (63-236) 4,111 (3,006-7,664)
1998   38        (21-214) 1,864 (1,153-7,052)
1999   12          (5-162)    682    (388-5,909)
2000     3            (1-86)    221    (128-3,660)
2001     1            (0-33)     72      (45-1,592)
aBovine spongiform encephalopathy.
bInformation extracted from (7).
Table 3. Number of cases of feline spongiform
encephalopathy in the United Kingdom by year of
diagnosis (MAFF, personal communication)
Year Number of cases
1990 12
1991 12
1992 10
1993 11
1994 16
1995   8
1996   6
1997   6
1998a   4
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after the ban on specified bovine offal in pet food.
A TSE indistinguishable from BSE has also been
found in puma, cheetah, ocelot, and a tiger in zoos in
the United Kingdom between 1992 and 1995. These
animals became infected as a result of being fed raw
meat, which would have included bovine central
nervous system, a practice which has now ceased.
Human Disease and BSE
Control Measures
The risk to human health from BSE was
always recognized. The principal protective
measure was the November 1989 ban on the use
of certain specified bovine offal in human food. As
with scraple, the tissues banned were those likely
to contain the highest concentrations of the
transmissible agent (brain, spinal cord, tonsil,
spleen, thymus, and intestine of cattle older than
6 months of age). The intestine and thymus of
calves was added to the list in 1994 when a long-
term pathogenesis study in cattle by the Ministry
of Agriculture, Fisheries and Food indicated that
the transmissible agent could be found in the
terminal ileum (it is assumed that the agent was
present in Peyer’s patches). In 1996 the whole
head, other than the tongue, was formally
banned because of concern about possible
contamination with brain. Since the banned
tissues now contain more than offal, the tissues
are referred to as specified bovine material.
During 1995, it became clear that spinal cord was
not being completely removed from a small
number of carcasses that were subsequently
certified as fit for human consumption. Conse-
quently, in December 1995 the U.K. government
banned the use of bovine vertebral column for the
production of mechanically recovered meat. In
March 1996, when it became clear that human
disease related to BSE was “probable” rather
than “theoretical,” the U.K. government intro-
duced the over-30–month scheme, which allowed
only animals under the age of 30 months to be
used for human food, provided that all the banned
specified bovine material had been removed. This
added an extra margin of safety because cattle
can be reasonably accurately aged by their
dentition at 30 months and because BSE is
relatively rare under the age of 30 months. Only
265 cases occurred in cattle younger than 30
months, and during 1997, the youngest animal
with BSE was 37 months of age (Ministry of
Agriculture, Fisheries and Food, pers. comm.). In
the second half of 1997, the long-term
pathogenesis experiment indicated that the
transmissible agent of BSE could be recovered
from the dorsal root ganglia of experimentally
infected animals toward the end of the incubation
period. Also, in one animal the agent was
transmitted by intracerebral inoculation of mice
with bovine bone marrow. Accordingly, in
December 1997 the U.K. government introduced
legislation to ban the sale of beef on the bone,
even from animals under 30 months of age. Many
in the United Kingdom thought that this
regulation to prevent an extremely small risk of
transmitting BSE in T-bone steaks and rib of beef
was unnecessary. Nevertheless, the introduction
of the specified bovine offal ban in 1989 and its
subsequent refinements have ensured the safety
of beef and beef products that now enter the
human food chain in the United Kingdom. Even
so, as a consequence of the emergence of new
variant CJD, a worldwide ban on the sale of U.K.
beef and beef products was introduced by the
European Union in March 1996 and is still in
force with the exception of a recent (March 1998)
relaxation for certain herds in Northern Ireland.
New Variant CJD
Clearly, the first measures to protect human
health were introduced before any human
disease could be related to BSE. To guard against
the possible emergence of such disease (or
diseases), the U.K. Department of Health set up a
CJD Surveillance Unit in 1990. The purpose of
the unit was to monitor the trends in incidence of
CJD and any unusual features among cases.
Concern was first focused on the 1995 cases of the
third and fourth U.K. farmer since 1990 to be
confirmed as having CJD. Statistically, the
chances of four such cases occurring in 6 years in
the United Kingdom were very small. However,
the clinical features of the disease were typical of
classical CJD, and collaboration between the CJD
Surveillance Unit and other European countries
indicated that farmers were overrepresented
compared with CJD cases in countries with no
BSE. Subsequently, classic CJD was confirmed in
these farmers; no further cases have been
diagnosed in U.K. farmers, and the significance of
the high incidence in 1995 is diminishing.
The death in May 1995 of the first adolescent
ever to be diagnosed with CJD in the United
Kingdom was followed in October 1995 by the
death of a second adolescent; by January 1996,393 Vol. 4, No. 3, July–September 1998 Emerging Infectious Diseases
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three other young (29 years of age) persons
became ill. Atypical pathologic results were
beginning to be defined in these patients; and on
March 8, 1996, eight cases of what came to be
known as new variant CJD or variant CJD
(vCJD) were reported to the Spongiform
Encephalopathy Advisory Committee. The cases
were distinguished by the relatively young age at
which the symptoms started (10,11). That age
range is now 16 years to 52 years. The duration of
the illness is relatively long, averaging approxi-
mately 14 months as opposed to the 4 to 5 months
in classic CJD. The early symptoms are often
psychiatric, and it may be 6 or 7 months before
any neurologic signs appear. The characteristic
electroencephalogram pattern of sporadic CJD is
not seen in vCJD, and pathologic results show
florid plaques and extensive cerebellar involve-
ment with multiple PrP deposits. As with BSE
and FSE, the neuropathologic appearances are the
mainstay of laboratory confirmation. Magnetic
resonance imaging scanning and detection of 14-3-
3 protein can be helpful. Early evidence indicates
that the diagnosis can often be made from tonsil
biopsies (12). Otherwise, diagnosis must depend
upon brain biopsy or postmortem examination.
When on March 20, 1996, the U.K.
government announced the existence of 10 cases
of vCJD and the opinion of the Spongiform
Encephalopathy Advisory Committee that these
were probably related to BSE, three questions
immediately arose. The first was, “Is there really
any link with BSE?” Additional evidence
emerged from the work of Collinge and his
colleagues (13) on the analysis of the PrP
fragments after protease digestion. The position
of the three fragments and the relatively high
concentrations of the di-glycosylated form
indicated that vCJD was distinct from the
previously recognized forms of CJD and that
similarities existed between the cases of vCJD
and BSE and FSE. In 1997, the first results were
published from the classic strain typing
experiments initiated during 1996 (14). The
characteristics of material from cases of vCJD, in
terms of incubation period and lesion profile in
RIII mice, were identical to those from cases of
BSE and FSE. These observations are confirmed
now in C57 black mice. Thus, vCJD can now be
regarded as human BSE in the same way that
FSE is regarded as feline BSE. The second
question was, “What is the route of transmission
from cattle to humans?” So far we have no
evidence, only a working hypothesis, that
transmission was likely from inclusion in the
human food chain of tissues that contain the
highest concentration of the transmissible agent.
The major differences in human exposure to
these tissues would have occurred first when sick
animals were banned from the human food chain
in 1988 and again in 1989 when the specified
bovine offals of otherwise healthy animals were
removed from the human food chain.
Studies continue in an attempt to answer the
third question, “How many vCJD cases will there
be in the future?” So far, 26 cases have been
diagnosed in the United Kingdom (Table 4) and 1
in France. Incidence has not increased since
vCJD was first diagnosed in 1995. If instead of
looking at the date of death one looks at the date
of onset of the symptoms in the 26 patients, two
new cases occurred on average every quarter
since 1994. All cases have been methionine
homozygotes at codon 129 of the PrP gene. In the
general population approximately 40% have such
a genotype; 10% are valine homozygotes, and 50%
are heterozygotes. An analysis of classic sporadic
CJD indicates that 80% of those cases are
methionine homozygotes, 10% valine homozy-
gotes, and 10% heterozygotes. It is perhaps not
surprising, therefore, that the first cases of vCJD
to be seen are methionine homozygotes.
Only one published analysis has predicted
the number of future nvCJD cases after
constraining the models used to the known and
surmised facts at the time (15). The total number
of future cases will depend critically on the
average incubation period of vCJD. At present,
we have no way of determining that; therefore, it
remains too early to predict with any accuracy
the total number of future cases. It remains
possible that the outbreak of vCJD cannot be
regarded as a single curve and that the small
Table 4. Creutzfeldt-Jakob disease in the United Kingdom
Deaths of definite and probable cases
Refer-Spora- Iatro- Fami-
Year rals dic genic lial GSSa nvCJDbTotal
1994 116 52 1 3 3   0 59
1995   86 34 4 2 3   3 46
1996 133 40 4 2 4 10 60
1997 152 42 6 3 0 10 61
1998c   35   3 0 1 0   2   6
aGerstmann-Straussler-Scheinker syndrome.
bNew variant Creutzfeldt-Jakob disease.
cTo Apr 30, 1998. Figures released by U.K. Department of
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number of cases have occurred in persons who are
extremely susceptible for unknown reasons.
The Future
Much has happened already as a consequence
of the emergence of BSE in U.K. cattle. The
appropriate measures are in place to protect
public health and end the BSE epidemic in cattle
and other affected species. These measures are
more rigorously enforced than ever before. It is
difficult to see what could be done to make the
BSE epidemic decline more rapidly than it
already has, short of slaughtering the entire U.K.
herd, which would be unnecessary and impracti-
cal. From now the question is likely to be how to
withdraw some of the restrictions on U.K. beef
and beef products. The exemptions are likely to
be herd based (as is the case with Northern
Ireland) or date based after the total ban on the
use of meat and bone meal in the feed of any farm
animals in the United Kingdom in 1996. In terms
of the protection of public health, all the
necessary measures are in place. Two further
concerns remain and are actively under
consideration: whether or not BSE exists in the
sheep flocks and whether the cases of vCJD in the
United Kingdom will be sufficient to generate
concern about a second wave of transmission
within the human population as a consequence of
the use of blood and blood products. With respect
to the former, the detection of sheep with scrapie-
like diseases in the United Kingdom and the
typing of strains from affected animals are being
intensified. With respect to blood and blood
products, some restrictions on the use of U.K. raw
materials for the production of blood products are
already in place, and a detailed risk assessment
in relation to blood transfusion is awaited.
Sir John Pattison is a virologist and dean of the
Medical School, University College London, and Chair,
U.K. Spongiform Encephalopathy Advisory Committee.
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